What ScreenIn3D does

ScreenIn3D Limited is a Glasgow-based precision medicine company that has developed UpScale3D®, a patented lab-on-a-chip screening platform combining microfluidic technology with 3D cell culture for drug discovery applications. The platform supports spheroids, organoids, and 3D co-cultures built from patient-derived tissue, and is differentiated by shear-stress-free perfusion that requires no tubing, syringe pumps, or rocking plates, miniaturization that yields at least 20 times more data than standard methods using only a few thousand cells, and a microplate form factor designed to be plug-and-play with standard imaging equipment and robotic dispensers. Founded in 2018 as a spin-off of the University of Strathclyde, the company serves pharmaceutical and biotech customers developing small molecules, biologics, and cell and gene therapies across oncology (glioblastoma, breast, endometrial, colorectal, ovarian, prostate, and lung cancers), immuno-oncology (including CAR-T), and women's health (endometriosis and fibroid disease).

The company operates a B2B professional-services business model, monetizing through quote-based custom contracts. Its revenue streams include 3D in vitro drug efficacy screening, custom assay design, 3D co-culture development using patient-derived tissue, and single and combination drug testing (including chemo- and radio-therapy regimens). Distribution is via direct enterprise sales supplemented by CRO partnerships, most notably a strategic co-development alliance with RoukenBio in immuno-oncology, and a partnership with Inaphaea BioLabs that gives ScreenIn3D access to over 470 patient-derived cells across 66 cancer types. Pricing is not publicly disclosed and there is no self-serve or e-commerce channel.

ScreenIn3D is a small, privately held company of approximately 10 employees, led by co-founders Prof. Michele Zagnoni (CEO) and Alex Sim (Chairman), with a senior engineer, senior scientist, scientist, and additional team members, plus investor director Fiona Nicolson. It is backed by the University of Strathclyde alongside Scottish Enterprise, TRICAPITAL (lead investor in a June 2025 round), Gabriel Investments, and Nidobirds Ventures, with a total disclosed funding round of approximately $1.02M. AstraZeneca (through Steve Rees, VP Discovery Biology) is the only named enterprise validation customer, citing direct applicability of the technology in target discovery, combination screening, and treatment regime determination.

Name

ScreenIn3D

Legal name

ScreenIn3D Limited

Website

https://screenin3d.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

ScreenIn3D is a Glasgow-based precision medicine company offering the patented UpScale3D® lab-on-a-chip platform and 3D cell-culture screening services to pharmaceutical and biotech clients developing drugs across oncology, immuno-oncology, and women's health.

Ownership category

akta.pro rank

Product category

Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)

akta.pro secondary industries

Cell-Based & Potency Assays (Bioassays) (HLAGADAH), Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Drug screening services
• 3D cell culture
• Microfluidic screening platform
• Lab-on-a-chip technology
• Preclinical drug discovery

Headquarters

HQ city

Glasgow

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. 3D In Vitro Drug Efficacy Screening Services: Provides contracted screening services using the UpScale3D platform. Guides clients on disease model generation, defines assay conditions, and delivers results. Revenue generated through service contracts for drug efficacy testing on 3D translational models.
2. Custom Assay Development: Collaborative assay design services tailored to client study goals. Includes sequential cell seeding for time-dependent modeling and scalable drug testing across 3D models.
3. 3D Co-Culture Development: Generation of tumoroids and complex 3D in vitro models using patient-derived tissue for evaluating compound effects across biological systems.
4. Drug Combination Screening: Single and combination drug testing services including chemo- and radio-therapy regimens, mimicking clinical dosing protocols in vitro.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

ScreenIn3D commercializes the patented UpScale3D® lab-on-a-chip platform and offers contract screening services that test drug efficacy on miniaturized 3D human disease models (spheroids, tumoroids, organoids). The company combines microfluidic technology with patient-derived tissue to deliver high-throughput drug efficacy, custom assay development, 3D co-culture, and combination drug screening services to pharmaceutical and biotechnology customers.

Product overview

ScreenIn3D offers the UpScale3D® patented lab-on-a-chip platform as its core product, which provides a microplate-based screening system with image analysis software for large-throughput 3D drug screening. This platform is complemented by a suite of service offerings including 3D in vitro drug efficacy testing, development of 3D co-cultures, custom assay design, and single/combination drug testing services. The platform supports multiple therapy modalities including small molecules, biologics, and cell and gene therapies, with applications spanning oncology, immuno-oncology, and women's health disease models.

Differentiator

Problem solved

Functional benefit

Brands

• UpScale3D: Patented lab-on-a-chip screening platform technology with associated image analysis software for cost-effective, high quality, large-throughput and data-rich assays.

Products and services

• UpScale3D® Patented lab-on-a-chip screening platform with associated image analysis software that enables cost-effective, high-quality, large-throughput, data-rich 3D drug screening assays in a microplate format compatible with existing imaging equipment and robotic dispensers. Used by pharmaceutical and biotech customers to test drug efficacy on 3D disease models.
• 3D In Vitro Drug Efficacy Screening Contracted screening service that miniaturizes and upscales generation of 3D translational in vitro models with drug efficacy testing and assay-specific readouts. Sold to pharmaceutical and biotech customers for preclinical drug discovery.
• 3D Co-Culture Development Generation of tumoroids and complex 3D in vitro models using patient-derived tissue that simulate cell-cell interactions and quantify cell-drug responses at scale. Sold to pharma and biotech customers developing oncology and immuno-oncology therapies.
• Custom Assay Design Tailored assay development collaboration that builds assays reflecting real disease complexity, with sequential cell seeding and scalable drug testing across 3D models. Sold to pharma and biotech clients requiring bespoke preclinical assays.
• Single & Combination Drug Screening Evaluation of compounds alone or in combination, including multi-format combination screening with chemo- and radio-therapy regimens that mimic clinical dosing protocols in vitro. Sold to pharma and biotech clients for preclinical candidate selection.
• CAR-T 3D Assay Service High-throughput miniaturized CAR-T cell therapy efficacy assays that test cytotoxicity of T-cell therapies on spheroid co-cultures and organoids. Sold to immuno-oncology and cell therapy developers needing predictive preclinical CAR-T models.

Quantifiable outcome

• 20X more data for the same starting material
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• RoukenBiocoreStrategic or Co-development PartnerStrategic partnership between ScreenIn3D and RoukenBio delivering next-generation 3D in vitro platforms for immune-oncology. Combines RoukenBio's immunology expertise and bespoke assay development with ScreenIn3D's cutting-edge 3D miniaturized microfluidic technology. Enables advanced physiologically relevant assays that accelerate and de-risk drug discovery efforts for CAR-T and immunotherapy testing.
• Inaphaea BioLabscoreStrategic or Co-development PartnerStrategic partnership providing patient-derived cells (PDCs) and cell-based assays focused on oncology and women's health. Inaphaea offers over 470 PDCs across 66 types of cancer from its biobank. Partnership supports translational drug development by providing data-driven insights into cancer cell activity using ScreenIn3D's screening platform.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Kiyatec: Provides 3D cell-based predictive drug response assays for oncology drug development, sharing ScreenIn3D's emphasis on human-relevant 3D ex vivo prediction in cancer screening.
• SynVivo: Builds microfluidic organ-on-chip devices for drug delivery and screening research, with overlapping lab-on-a-chip technology and pharma customer base.

Direct peers

• TissUse: Develops multi-organ-chip and microphysiological platforms for preclinical drug testing, competing in microfluidic organ-on-chip drug screening for pharmaceutical customers.
• CN Bio Innovations: Provides organ-on-chip and microphysiological systems for preclinical drug discovery, directly overlapping with ScreenIn3D's UpScale3D microfluidic 3D culture platform in target customers and use cases.
• MIMETAS: Develops OrganoPlate microfluidic 3D tissue models for high-throughput drug screening, offering an overlapping organ-on-chip service and product model for pharma preclinical testing.
• Emulate Inc. Commercializes the Emulate organ-chip platform for human-relevant disease modeling and drug discovery, competing for the same pharma preclinical 3D screening budget as ScreenIn3D.
• InSphero: Provides 3D spheroid and organoid-based assay services and platforms for drug discovery, directly comparable to ScreenIn3D's 3D in vitro disease model screening offering.

Broad incumbents

• Crown Bioscience (JSR Life Sciences): Large preclinical CRO offering in vivo and in vitro oncology services including 3D model screening; an incumbent alternative for pharma customers evaluating specialized 3D providers like ScreenIn3D.
• Molecular Devices (Danaher): Supplies high-throughput screening instruments and software for drug discovery, representing a broad incumbent whose microplate readers and automation ecosystem compete for the same screening workflow budgets.

Others

• RoukenBio: Strategic immunology CRO partner of ScreenIn3D; comparable as a UK-based specialist immuno-oncology assay CRO addressing the same pharma customer segment through complementary capabilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/screenin3d
• LinkedInlinkedin.com/company/screenin3d

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ScreenIn3D